Hirano T
Ibaraki Children's Hospital.
Nihon Rinsho. 1997 Nov;55(11):2952-7.
Constitutional delay of growth and puberty (CDGP), featuring short stature, delayed puberty and delayed bone age, is the most common condition in pediatric endocrine clinic and becomes an important differential diagnosis in boys with short stature. The conventional management is to assure eventual development of puberty and normal final stature. Treatment with androgens to induce secondary sex characteristics is given only when the boy is under psychosocial stress. Recent reports revealed poor final height outcomes. The results of growth hormone treatment in idiopathic short stature, including CDGP, has not been successful. New findings showed that adults with a history of delay puberty had significant osteopenia and may have a risk of fracture, and that suppression of spinal growth was closely related to pubertal delay, leading to short stature. These two facts suggest the necessity of induction of puberty in normal timing.
体质性生长和青春期延迟(CDGP),其特征为身材矮小、青春期延迟和骨龄延迟,是儿科内分泌门诊最常见的病症,也是身材矮小男孩的重要鉴别诊断。传统治疗方法是确保青春期最终发育和正常的最终身高。仅当男孩处于心理社会压力之下时,才给予雄激素治疗以诱导第二性征。近期报告显示最终身高结果不佳。生长激素治疗特发性矮小(包括CDGP)的结果并不成功。新的研究结果表明,有青春期延迟病史的成年人存在明显的骨质减少,可能有骨折风险,并且脊柱生长受抑制与青春期延迟密切相关,导致身材矮小。这两个事实表明正常时间诱导青春期的必要性。